| 刊名 | Medicinal Plant |
| 作者 | Ziyi DU,Xiaoqiang ZHANG,Hong ZHANG,Xuan LIU,Pingping TIAN |
| 作者单位 | Graduate School of Shanxi University of Chinese Medicine; Shanxi Traditional Chinese Medical Hospital; Department of Rheumatology, Affiliated Hospital of Shanxi University of Chinese Medicine; Dongzhimen Hospital International Department of Beijing University of Chinese Medicine |
| DOI | DOI:10.19600/j.cnki.issn2152-3924.2026.04.007 |
| 年份 | 2026 |
| 刊期 | 4 |
| 页码 | 30-36，39 |
| 关键词 | Jianzhong Chubi Decoction, Knee osteoarthritis (KOA), Chronic gastritis (CG), Network pharmacology, Molecular docking, Comorbidity |
| 摘要 | [Objectives] To explore the mechanisms of Jianzhong Chubi Decoction in treating comorbid knee osteoarthritis (KOA) and chronic gastritis (CG) based on network pharmacology and molecular docking approaches. [Methods] Active components and their corresponding targets of Jianzhong Chubi Decoction were retrieved from the TCMSP and SymMap databases. Disease targets for KOA and CG were collected from GeneCards. Overlapping targets were used to construct a “drug–active component–target” network and a protein-protein interaction (PPI) network. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. Molecular docking was subsequently conducted to validate the binding affinities between the core active components and key targets. [Results] A total of 104 active components and 440 targets were obtained for Jianzhong Chubi Decoction, along with 1 500 KOA targets and 1 000 CG targets, yielding 98 intersecting targets. The core components were quercetin, kaempferol, and feruloyltyramine; the key targets included TNF, AKT1, IL-6, and IL-1β. KEGG enrichment analysis mainly involved cancer pathways, lipid and atherosclerosis pathways, and the AGE-RAGE signaling pathway. Molecular docking showed that the binding energies of the core components with the key targets were all below −5 kcal/mol. [Conclusions] Jianzhong Chubi Decoction exerts anti-inflammatory, cartilage-protective, and gastric mucosa-protective effects through multiple components, multiple targets, and multiple pathways. This provides a pharmacological basis for the concept of “treating different diseases with the same therapy” in KOA and CG comorbidity. |
